Richard Newmark
Overview
Explore the profile of Richard Newmark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Targan S, Feagan B, Vermeire S, Panaccione R, Melmed G, Landers C, et al.
Am J Gastroenterol
. 2016 Aug;
111(11):1599-1607.
PMID: 27481309
Objectives: To assess the safety and efficacy of brodalumab, a human anti-interleukin-17 receptor monoclonal antibody, in patients with moderate-to-severe Crohn's disease (CD). Methods: Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study...
2.
Pavelka K, Chon Y, Newmark R, Lin S, Baumgartner S, Erondu N
J Rheumatol
. 2015 Apr;
42(6):912-9.
PMID: 25877498
Objective: To evaluate the efficacy and safety of brodalumab, a human monoclonal antibody inhibitor of the interleukin 17 receptor, in subjects with rheumatoid arthritis (RA). Methods: Patients (n = 252)...
3.
Mease P, Genovese M, Greenwald M, Ritchlin C, Beaulieu A, Deodhar A, et al.
N Engl J Med
. 2014 Jun;
370(24):2295-306.
PMID: 24918373
Background: We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic...
4.
Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis
Sharp J, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R
Arthritis Care Res (Hoboken)
. 2010 Apr;
62(4):537-44.
PMID: 20391509
Objective: Osteoclast-mediated bone loss in the hand predicts future bone erosions in patients with rheumatoid arthritis (RA). Osteoclast activity depends on RANKL, which is inhibited by denosumab, an investigational fully...
5.
Dore R, Cohen S, Lane N, Palmer W, Shergy W, Zhou L, et al.
Ann Rheum Dis
. 2009 Sep;
69(5):872-5.
PMID: 19734132
Objectives: To report results of subgroup analyses of bone mineral density (BMD) and bone turnover markers from a randomised, double-blind, placebo-controlled, phase II study of denosumab, an investigational RANKL inhibitor,...
6.
Brown J, Prince R, Deal C, Recker R, Kiel D, de Gregorio L, et al.
J Bone Miner Res
. 2008 Sep;
24(1):153-61.
PMID: 18767928
Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, a key mediator of osteoclast formation, function, and survival. This phase 3, multicenter, doubleblind study compared...
7.
Cohen S, Dore R, Lane N, Ory P, Peterfy C, Sharp J, et al.
Arthritis Rheum
. 2008 Apr;
58(5):1299-309.
PMID: 18438830
Objective: RANKL is essential for osteoclast development, activation, and survival. Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized,...
8.
Bresnihan B, Newmark R, Robbins S, Genant H
J Rheumatol
. 2004 Jun;
31(6):1103-11.
PMID: 15170922
Objective: To determine the effects of treatment on the radiologic manifestations of joint damage in patients with rheumatoid arthritis (RA) who participated in a 24-week extension study of a randomized,...
9.
Genovese M, Cohen S, Moreland L, Lium D, Robbins S, Newmark R, et al.
Arthritis Rheum
. 2004 May;
50(5):1412-9.
PMID: 15146410
Objective: To determine the potential for additive or synergistic effects of combination therapy with the selective anti-tumor necrosis factor alpha agent etanercept and the anti-interleukin-1 agent anakinra. Methods: Two hundred...